Lung cancer patients get new hope with experimental combo therapy
NCT ID NCT04884282
First seen Feb 06, 2026 · Last updated May 12, 2026 · Updated 7 times
Summary
This study tests two drug combinations (Tedopi plus docetaxel or Tedopi plus nivolumab) as a second treatment option for people with advanced non-small-cell lung cancer whose cancer worsened after initial chemo-immunotherapy. About 105 adults with a specific genetic marker (HLA-A2+) will participate. The goal is to see if these combos improve survival compared to standard docetaxel alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AO Busto Arstizio PO Saronno
Saronno, Varese, Italy
-
AOOR Papardo-Piemonte
Messina, Italy
-
AOU "Maggiore della Carità"
Novara, Italy
-
ASST Sette Laghi
Varese, Italy
-
Azienda Ospedaliera di Perugia
Perugia, Italy
-
Azienda Ospedaliero-Universitaria Careggi
Florence, Italy
-
Centre Hospitalier de Cholet
Cholet, 49300, France
-
Clinica Mi Tres Torres - UOMI Cancer Center
Barcelona, 08017, Spain
-
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña, 15006, Spain
-
GHR Mulhouse Sud Alsace - Hôpital Emile Muller
Mulhouse, 68100, France
-
Hospital Universitario La Paz
Madrid, 28046, Spain
-
Hospital Universitario Regional de Málaga - Hospital Civil
Málaga, 29011, Spain
-
Hospital de Mataró
Mataró, 08304, Spain
-
IRCCS - Arcispedale Santa Maria Nuova
Reggio Emilia, Italy
-
Institut Sainte Catherine
Avignon, 84918, France
-
Istituto Nazionale Tumori "Regina Elena"
Roma, 00144, Italy
-
Istituto Oncologico Veneto
Padova, 35128, Italy
-
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
Meldola, Forlì, 47014, Italy
-
Nouvel Hôpital Civil - Hopitaux Universitaires de Strasbourg
Strasbourg, 67091, France
-
Ospedale Mater Salutis Legnago
Legnago, Verona, 37045, Italy
-
Ospedale Sacro Cuore Don Calabria
Negrar, Verona, Italy
-
Ospedale San Paolo
Civitavecchia, Italy
-
Vall d'Hebron Universitary Hospital
Barcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.